Reach Us +44-1647-403003
Economic Analysis: Randomized, Placebo-Controlled Clinical Trial of Dutasteride in Men at High Risk for Prostate Cancer | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Economic Analysis: Randomized, Placebo-Controlled Clinical Trial of Dutasteride in Men at High Risk for Prostate Cancer

Costel Chirila1*, Stephanie R. Earnshaw1, Libby Black2, Cheryl McDade1, Neil Roskell3, Paul Shannon3, Francesco Montorsi4and Gerald L. Andriole5

1RTI Health Solutions, PO Box 12194, Research Triangle Park, NC 27709, USA

2GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA

3RTI Health Solutions, 2nd Floor, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, United Kingdom

4Universitá Vita Salute San Raffaele, Via Olgettina 60, 20132 Milan, Italy

5Division of Urology, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center, 4960 Children’s Place, Campus Box 8242, St. Louis, MO 63110

*Corresponding Author:
Costel Chirila
RTI Health Solutions
PO Box 12194
Research Triangle Park
NC 27709, USA
Tel: +1.919.541.8083
Fax: +1.919.541.7222
E-mail: [email protected]

Received Date: November 10, 2011; Accepted Date: December 09, 2011; Published Date: December 11, 2011

Citation: Chirila C, Earnshaw SR, Black L, McDade C, Roskell N, et al. (2011) Economic Analysis: Randomized, Placebo-Controlled Clinical Trial of Dutasteride in Men at High Risk for Prostate Cancer. J Cancer Sci Ther S3:004. doi: 10.4172/1948-5956.S3-004

Copyright: © 2011 Chirila C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Objective: Given the economic burden of prostate cancer (PCa), a PCa risk-reduction medication would be desirable. A within-trial economic analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was performed.

Methods: REDUCE, a 4-year, randomized, double-blind, placebo-controlled, parallel-group clinical trial, compared efficacy and safety of dutasteride 0.5 mg daily and placebo to reduce the risk of PCa in men at increased risk. Resource use was prospectively collected; costs from standard costing sources were applied. Utilities were obtained from published literature. Relative risks and Wilcoxon rank sums were used to examine differences between treatments.

Results: Placebo patients were at significantly higher risk (P < 0.05) for concomitant medication use; and health care visits related to surgical procedures, unscheduled biopsies, acute urinary retention, urinary tract infections, or macroscopic hematuria. Total costs were significantly lower (P < 0.001) in dutasteride patients ($1 300; 95% confidence interval: $806, $1 795). Incremental cost per quality-adjusted life-year (QALY) was $26 516; cost per PCa case avoided was $19.

Conclusions: During the 4-year trial period, men at increased risk for PCa receiving dutasteride incurred fewer health care costs than men receiving placebo, which helped offset dutasteride costs. Dutasteride was good value for money.


Share This Page